Health Canada has authorized Eli Lilly’s daily GLP-1 pill Foundayo for weight loss in adults with obesity or overweight and at least one related medical problem.
The Story
Health Canada has authorized Foundayo, a daily oral GLP-1 medication from Eli Lilly, for the treatment of weight loss.
The pill is approved for adults with obesity, as well as adults who are overweight and have at least one related medical condition, including high blood pressure or sleep apnea. In addition to promoting and maintaining weight loss, Foundayo is also approved to help treat Type 2 diabetes.
Foundayo’s active ingredient is orforglipron, a non-peptide GLP-1 receptor agonist. Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with either Eli Lilly or Novo Nordisk, said the smaller molecule allows orforglipron to be taken orally and absorbed without being broken down by the digestive system.
Ur said, “It seems to be just as good as if not better” for weight loss as semaglutide and tirzepatide.
The most common side effects of GLP-1 medications, whether injectable or oral, include gastrointestinal issues such as nausea or vomiting. Ur said whether he would prescribe Foundayo depends on the patient, in part because he is still waiting for clinical trial results on whether orforglipron has a cardiovascular benefit like semaglutide and tirzepatide.
Foundayo received Health Canada authorization on Nov. 13. Eli Lilly spokesperson Ethan Pigott said the company expects the pills to be available in pharmacies in January.
A second oral GLP-1 weight-loss option could follow, with Novo Nordisk’s Wegovy pill still awaiting Health Canada approval. Both Foundayo and the Wegovy pill are approved and available in the United States. Novo Nordisk said it can manufacture Wegovy in pill form by adding salcaprozate sodium, known as SNAC, to help protect it from being broken down by digestive enzymes, and that SNAC temporarily makes the area around the pill less acidic so it can pass through the stomach lining into the bloodstream.
← More stories